Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Methotrexate Hepatotoxicity in Children with Juvenile Idiopathic Arthritis: A Single-Center Study

Author(s): Noha Adel Yassin*, Mai Haroon and Azza Elhamshary

Volume 17, Issue 2, 2021

Published on: 11 December, 2020

Page: [242 - 246] Pages: 5

DOI: 10.2174/1573397116666201211123142

Price: $65

Abstract

Background: Juvenile idiopathic arthritis (JIA) could be disabling if left untreated. Methotrexate (MTX) is well known as a cornerstone in management. However, its adverse effects may limit treatment.

Objective: The objective of this study was to evaluate the frequency of hepatotoxicity based on liver chemistry in JIA children receiving MTX.

Methods: An observational case-control study of children with JIA who attend the Pediatric Rheumatology Unit, Cairo University Pediatric Hospital, Egypt, from January 2018 to December 2018 was carried out. Data were retrieved for 80 children; 50 (62.5%) were prescribed MTX. Their demographic, clinical characteristics, mean dose, duration of MTX therapy and other medications were described. Hepatotoxicity was defined as at least one value above the normal laboratory range of either ALT or AST during the study period.

Results: Fourteen patients developed hepatotoxicity, giving an incidence of 28%. Children receiving MTX had higher alanine aminotransferase (ALT) interquartile range (IQR) (26 [21-359] vs. 23[20-32]; p =0.003), higher aspartate aminotransferase (AST) interquartile range (IQR) (31 [22-267] vs. 28[2-35] IU/L; p <0.001), and lower alkaline phosphatase (ALP) mean (±SD) (98±35.5 vs. 256 ± 39.5 IU/L; p <0.001). However, there were no significant differences in age, sex, weight, type of JIA, and duration of MTX treatment (p< 0.05).

Conclusion: Hepatotoxicity due to MTX, based on liver chemistry, is common among children with JIA.

Keywords: Juvenile idiopathic arthritis, methotrexate, hepatotoxicity, single-center study, MTX, JIA.

« Previous Next »
[1]
Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009; 11(1): 216.
[http://dx.doi.org/10.1186/ar2619] [PMID: 19291269]
[2]
Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013; 65(2): 334-42.
[http://dx.doi.org/10.1002/art.37723] [PMID: 23044791]
[3]
Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009; 68(7): 1105-12.
[http://dx.doi.org/10.1136/ard.2008.099861] [PMID: 19054823]
[4]
Albrecht K, Müller-Ladner U. Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28(5)(Suppl. 61): S95-S101.
[PMID: 21044440]
[5]
Conway R, Carey JJ. Risk of liver disease in methotrexate treated patients. World J Hepatol 2017; 9(26): 1092-100.
[http://dx.doi.org/10.4254/wjh.v9.i26.1092] [PMID: 28989565]
[6]
British society for Rheumatology. Methotrexate use in paediatric and adolescent rheumatology Information for health professionals 2020. Available from: https://www.rheumatology.org.uk/Portals/0/Documents/Guidelines/Paediatric%20guidelines/Mexthotrexate_Paediatric_Adolescent_Rheumatology.pdf?ver=2020-03-19-150320-243
[7]
Sotoudehmanesh R, Anvari B, Akhlaghi M, Shahraeeni S, Kolahdoozan S. Methotrexate hepatotoxicity in patients with rheumatoid arthritis. Middle East J Dig Dis 2010; 2(2): 104-9.
[PMID: 25197521]
[8]
Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68(7): 1100-4.
[http://dx.doi.org/10.1136/ard.2008.093690] [PMID: 19060002]
[9]
Becker ML, Rosé CD, Cron RQ, Sherry DD, Bilker WB, Lautenbach E. Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. J Rheumatol 2010; 37(4): 870-5.
[http://dx.doi.org/10.3899/jrheum.090826] [PMID: 20194449]
[10]
Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006; 26(2): 55-62.
[http://dx.doi.org/10.2165/00044011-200626020-00001] [PMID: 17163236]
[11]
Diouf ML, Diallo S, Mbengue M, Moreira-Diop T. Methotrexate, liver and rheumatoid arthritis in tropical areas. Sante 2001; 11(3): 195-200.
[PMID: 11641084]
[12]
Al-Hemairi MH, Albokhari SM, Muzaffer MA. The Pattern of Juvenile Idiopathic Arthritis in a Single Tertiary Center in Saudi Arabia. Int J Inflamm 2016; 2016: 7802957.
[http://dx.doi.org/10.1155/2016/7802957] [PMID: 26966610]
[13]
Fujikawa S, Okuni M. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of a nationwide retrospective survey in Japan. Acta Paediatr Jpn 1997; 39(2): 245-9.
[http://dx.doi.org/10.1111/j.1442-200X.1997.tb03593.x] [PMID: 9141266]
[14]
Guzman J, Henrey A, Loughin T, et al. Predicting Which Children with Juvenile Idiopathic Arthritis Will Have a Severe Disease Course: Results from the ReACCh-Out Cohort. J Rheumatol 2017; 44(2): 230-40.
[http://dx.doi.org/10.3899/jrheum.160197] [PMID: 27980015]
[15]
Gheita TA, El-Gazzar II, El Shazly RI, El-Din AM, Abdel-Rasheed E, Bassyouni RH. Elevated serum resistin in juvenile idiopathic arthritis: relation to categories and disease activity. J Clin Immunol 2013; 33(1): 297-301.
[http://dx.doi.org/10.1007/s10875-012-9760-6] [PMID: 22886618]
[16]
Beath SV. The liver in systemic illness.Diseases of the liver and biliary system in children. (4th ed.). John Wiley and Sons Ltd 2017; pp. 369-88..
[http://dx.doi.org/10.1002/9781119046936.ch22]
[17]
Garnero P, Delmas DP. Investigation of bone: biochemical markers. Bone turnover in rheumatology. (3rd ed.). London, UK: Harcourt Health Sciences Ltd. 2003; pp. 995-1001..
[18]
Alkady EA, Rashad SM, Khedr TM, Mosad E, Abdel-Wahab N. Early predictors of increased bone resorption in juvenile idiopathic arthritis: OPG/RANKL ratio, as a key regulator of bone metabolism. Egypt Rheumatol 2011; 3: 217-23.
[http://dx.doi.org/10.1016/j.ejr.2011.08.001]
[19]
Falcini F, Ermini M, Bagnoli F. Bone turnover is reduced in children with juvenile rheumatoid arthritis. J Endocrinol Invest 1998; 21(1): 31-6.
[http://dx.doi.org/10.1007/BF03347283] [PMID: 9633020]
[20]
de Ridder CM, Delemarre-van de Waal HA, Waal HA. Clinical utility of markers of bone turnover in children and adolescents. Curr Opin Pediatr 1998; 10(4): 441-8.
[http://dx.doi.org/10.1097/00008480-199808000-00020] [PMID: 9757372]
[21]
Dehestani V, Shariati-Sarabi Z, Mohiti S, Akhlaghi S. Liver Toxicity in Rheumatoid Arthritis Patients Treated with Methotrexate. Asia Pac J Med Toxicol 2015; 4: 102-5.
[22]
Gaies E, Jebabli N, Trabelsi S, et al. Methotrexate Side Effects: Review Article. J Drug Metab Toxicol 2012; 3: 125.
[http://dx.doi.org/10.4172/2157-7609.1000125]

Rights & Permissions Print Cite
Article Metrics
10
© 2024 Bentham Science Publishers | Privacy Policy